Daiichi Sankyo licenses two abuse-deterrent painkillers from Inspirion to further its pain-management ambitions.

The roll-out of Samsung Bioepis' biosimilar version of blockbuster immunology drug Enbrel is going so well that analysts think additional manufacturing…

Another disciple of Valeant and its price-hiking credo is bidding farewell to its CEO.

Pressure is building in Japan for an out-of-cycle reduction in the price of Ono's cancer drug Opdivo.

Piramal added to its run of healthcare acquisitions with a $175 million deal to buy five injectable pain drugs from Johnson & Johnson.

Kyowa Hakko Kirin is rolling out the psoriasis med brodalumab this week in Japan, its first world market, but it faces a tough road ahead.

India's FMRAI union is calling for a mass strike by pharma sales reps in November as protests over working practices gather strength.

Sanofi and Regeneron’s next wannabe blockbuster is officially in regulators’ hands--but with the candidate tapped for a speedy review process, it may not stay…